Progress in Drug Research

Advances in Targeted Cancer Therapy

Editors: Schultz, Richard M. (Ed.)

Buy this book

eBook $249.00
price for USA (gross)
  • ISBN 978-3-7643-7414-3
  • Digitally watermarked, DRM-free
  • Included format: PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $319.00
price for USA
  • ISBN 978-3-7643-7174-6
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
About this book

There have been tremendous advances in our understanding of molecular and tumor biology during the past few years. In the field of cancer therapeutics, it is expected that cytotoxic drug approaches will be gradually replaced with treatments based on biological targeted approaches. Hopefully these new targeted therapies will significantly increase efficacy and lack the devastating and troublesome side effects elicited by cytotoxic chemotherapy.

This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed.
This volume should be of broad general interest to researchers and clinicians involved in cancer therapy as well as other scientists interested in current strategies for cancer treatment.

Table of contents (4 chapters)

  • Tumor models for preclinical development of targeted agents

    Beverly A. Teicher

    Pages 43-66

  • Targeted histone deacetylase inhibition for cancer prevention and therapy

    Carlo Palmieri, R. Charles Coombes, David M. Vigushin

    Pages 147-191

  • Antisense approaches in drug discovery and development

    Elizabeth Rayburn, Wei Wang, Ruiwen Zhang, Hui Wang

    Pages 227-274

  • Preclinical development of Alimta™ (Pemetrexed, LY231514), a multitargeted antifolate

    Richard M. Schultz

    Pages 275-300

Buy this book

eBook $249.00
price for USA (gross)
  • ISBN 978-3-7643-7414-3
  • Digitally watermarked, DRM-free
  • Included format: PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $319.00
price for USA
  • ISBN 978-3-7643-7174-6
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Advances in Targeted Cancer Therapy
Editors
  • Richard M. Schultz
Series Title
Progress in Drug Research
Series Volume
63
Copyright
2005
Publisher
Birkhäuser Basel
Copyright Holder
Birkhäuser Basel
eBook ISBN
978-3-7643-7414-3
DOI
10.1007/3-7643-7414-4
Hardcover ISBN
978-3-7643-7174-6
Series ISSN
0071-786X
Edition Number
1
Number of Pages
VII, 303
Topics